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Abstract – Serotonin has an important role in the development of depressive disorders. Bearing in mind that 
direct testing of central nervous system is unavailable to researchers due to the inability to reach the sam-
ples, ever greater attention is given to the peripheral systems that can help us diagnose and detect changes 
of the disease, but also follow the course of its treatment and recovery. Thrombocyte is a blood cell that con-
tains serotonin lodged in its delta granules. Thrombocyte serotonin system is similar, although not the same 
as the serotonin system in central nervous system. The most important differences are that in thrombocytes, 
serotonin is broken down by the enzyme monoaminooxidase B (MAO-B), while that function in neuron is 
carried out by monoaminooxidase A (MAO-A) and that a thrombocyte cannot synthetize serotonin itself, be-
cause it lacks tryptophan hydroxylase. Nowadays, in the treatment of depressive disorders, mostly the selec-
tive inhibitors of serotonin uptake (SIPPS) are being used. The research has proved that therapy with those 
medications changes the concentration of serotonin in thrombocytes and changes the values of some throm-
bocyte indices. The thrombocyte serotonin is a powerful vasoconstrictor, which increases the cardiovascular 
risk and the probability of thrombogenesis. The mean volume of thrombocytes (MPV) is a positive index of 
thrombocyte activity and the increase of MPV represents an independent risk factor for the development 
of cardiovascular diseases. It is of enormous significance to recognize the depression in patients who suffer 
from cardiovascular diseases. Depression interferes with the recovery of those patients, because it reduces 
the personal engagement in it and disturbs patients’ compliance and the motivation for treatment. Besides 
the fact that the treatment with SIPPS leads to the regression of symptoms of depression, it also changes 
the concentration of thrombocyte serotonin and the mean volume of thrombocytes towards the values that 
reduce their role in pathogenesis of cardiovascular diseases, thus reducing the risk of re-occurrence of car-
diovascular incidents and improving the patients’ recovery.
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Introduction
Among the known neurotransmitters, se-
rotonin, norepinephrine and dopamine play 
the important roles in the development of  
psychiatric disturbances. The research so far 
has shown that this is not the matter of  con-
centrations themselves, but of  disbalance of  
concentrations between the neurotransmit-
ter systems in CNS (central nervous system). 
There is proof  that there is a decrease of  se-
rotonin, epinephrine and dopamine functions 
in patients suffering from the recurring de-
pressive episodes, while there is a hyperactiv-
ity of  norepinephrine and dopamine system 
in patients suffering from the bipolar affective 
disorder [1]. There is still a dilemma if  there 
were a hypo or hyperactivity of  serotonin 
system in generalized anxiety disorder [2,3].  
The agonists of  5HT1A receptors reduce the 
symptoms of  panic disorders, while the ac-
tivation of  5HT2C receptors induces a panic 
attack [4]. Hypersensitivity of  postsynaptic 
serotonin receptors plays an important role 
in obsessive-compulsive disorders [5]. Desta-
bilization of  serotonin system has been not-
ed also in posttraumatic stress disorders. This 
fact had been confirmed by the efficiency of  
SIPPS in its treatment [6]. Dysfunction of  se-
rotonin system is also present in some per-
sonality disorders, urge-control disturbances, 
feeding disorders and dementia. It seems that 
the negative symptoms in schizophrenia are 
due to a dysfunction of  serotonin system. In 
suicidal tendencies, the role of  serotonin sys-
tem is of  the greatest importance and numer-
ous post-mortem investigations had revealed 
lower concentrations of  serotonin and its 
main metabolite 5-hydroxyindolacetate acid 
(5-HIAA) in brainstem, nuclei raphe, puta-
men and hypothalamus [7]. Some research 
show that lower levels of  thrombocyte sero-
tonin are connected with suicidal behaviour 
of  depressive patients [8]. Numerous investi-
gations have shown that, among the patients 
who had suffered a myocardial infarction or 
other diseases of  cardiovascular system we 
can find depressive symptoms in the frame 
of  depressive reaction, but also a real depres-
sion in its fully-blown clinical form. Depres-
sion slows the recovery in those patients but, 
even more importantly, some indices had 
been found in patients suffering from de-
pression that it could be directly connected 
with an increased risk for the development 
of  cardiovascular diseases and complications 
during recovery. Thrombocyte serotonin is a 
strong vasoconstrictor and the research has 
shown that the treatment with selective in-
hibitors of  serotonin uptake (SIPPS) causes 
lowering of  its concentration, thus reducing 
its role in increasing the cardiovascular risk 
and causing the complications of  recovery. 
Also, the treatment of  depressive patients 
with SIPPS lowers the values of  MPV (mean 
platelet volume, mean thrombocyte cell vol-
ume), which had been recognized as an inde-
pendent risk factor for the development of  
myocardial infarction and stroke.
Serotonin system in thrombocytes
Enterochromafine cells are the only cells 
besides 5HT neurons, that synthetize sero-
tonin. They release it into the blood stream, 
from where it, bound to its transporter, goes 
mostly into the thrombocytes. Serotonin sys-
tem in thrombocytes is very similar to the one 
in neurons. It is a part of  the mechanism of  
thrombocyte response, which is actually a 
process of  shape change and aggregation of  
thrombocytes [9,10]. Thrombocytes contain 
about 99% of  total serotonin in circulation, 
so in physiological conditions, plasma lev-
els of  serotonin reflect the concentration of  
serotonin in thrombocytes. Human throm-
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bocytes contain averagely 150 to 600 ng of  
serotonin/109 thrombocytes [11]. Serotonin 
system of  thrombocytes is made of: sero-
tonin transmembrane carrier ( transporter), 
serotonin receptor, enzyme monoaminooxi-
dase and serotonin stored in delta granules. 
Serotonin enters the thrombocytes and ag-
gregates through actions of  two carriers [12]. 
Protein 5-HT carrier (5HTt) is located at the 
membrane of  thrombocyte and enables the 
intake of  serotonin and other endogenous 
amines, for example dopamine, from plasma 
to the cytoplasmic fluid of  thrombocytes [13]. 
After the active transport, serotonin can be 
partly subjected to enzymatic breakdown, 
catalyzed by MAO-B enzyme, located at the 
external side of  membrane of  thrombocyte 
mitochondria and partly stored in delta gran-
ules. Storage in delta granules is carried out 
through so called vesicular transporter, lo-
cated at the membrane of  the granules. This 
active transport is enabled by the highly ef-
ficient proton ATP-aze [14-16]. This mecha-
nism is equal to the serotonin intake in neu-
ron vesicles. In the complicated process of  
blood coagulation, serotonin is also involved. 
During the process of  coagulation, serotonin 
is released from delta granules of  thrombo-
cytes by process of  exocytosis. Similarly, be 
means of  exocytosis, serotonin is released 
from the synaptic vesicles during the chemi-
cal transmission. The research so far had re-
vealed 15 different 5HT receptors and they 
all belong to the family of  G protein recep-
tors, while on the surface of  thrombocytes, 
there is only 5HT2A receptor, which is the 
binding place for serotonin and antidepres-
sants - inhibitors of  serotonin active trans-
port [17]. Binding of  serotonin, as an agonist 
of  5HT receptors, induces the thrombo-
cytes’ response, consisting of  release reaction 
and increased aggregation of  thrombocytes, 
during which the thrombocytes also change 
their shape. Serotonin also shows the ability 
to strengthen the thrombocytes’ response in 
the presence of  other agonists. Antagonists 
of  5HT2A receptors at the periphery show an 
anti-migraine effect. They are also used in the 
treatment of  asthma and for controlling the 
carcinoid tumors [18]. In CNS, 5HT2A recep-
tors are located in the cortex and play a role 
in sensory perception. Activation of  those 
receptors is connected with the loss of  appe-
tite and the occurrence of  anxiety and panic 
[19]. Antagonists of  5HT2A receptors in CNS 
show an antidepressive, but also antipsychot-
ic, anxiolytic and hypnotic effect.
Development of thrombocytes and 
thrombocyte indices
The lifespan of  thrombocytes in the pe-
ripheral blood flow equals 9-11 day [20]. Nor-
mal number of  thrombocytes is 250x 10 na 9 
/L, mean diameter is about 1-2 micrometers 
and the mean cell volume is 8 fl. Thrombo-
cytes are the only blood cells that reach their 
full number already in the fetal blood [21]. 
Pluripotent stem hematopoietic cell is the 
destination cell, which differentiates in imma-
ture cells of  myelopoetic and lymphopoetic 
system, from which the functionally mature 
cells, like erythrocytes, granulocytes, mono-
cytes, thrombocytes and lymphocytes T, get 
differentiated through the processes of  pro-
liferation and maturation. The least mature 
cell that shows the morphological character-
istics of  the thrombocyte strain is a mega-
karyoblast. The next developmental form is a 
megakaryocyte, which is the biggest hemato-
poietic cell, already containing the thick gran-
ules or delta granules, filled with, among oth-
er things, serotonin. Megakaryocyte is a cell 
that does not proliferate. It has got multiple 
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endomytoses and a very high DNA content. 
The final destiny of  megakaryocytes during 
maturation is releasing the thrombocytes 
into the bloodflow.Prothrombocyte theo-
ry implies the creation of  prothrombocyte 
through the long protrusions of  the cyto-
plasm of  megakaryocytes. In the final stage, 
which lasts about 5-10 hours in already con-
verted cytoplasm with intracellular content, 
the filaments connect the already formed 
thrombocytes with the cytoplasm of  pro-
thromobocytes, and after these filaments 
are ruptured, thrombocytes get released 
to the blood flow. From the beginning of  
differentiation of  the hematopoietic stem 
cell to the creation of  thrombocyte, about 
ten days pass. Each megakaryocyte creates 
5-10 thousands of  thrombocytes. They are 
shaped like a disk and contain neither nu-
cleus, nor endoplasmic reticulum and Golgi 
bodies. Glycocalix is a fluffy wrapping that 
covers the peripheral zone of  thrombocytes. 
It contains plasma proteins and factors of  
coagulation, fibrinolysis and complement. 
Below the glycocalix is a negatively charged 
thrombocyte membrane, consisting of  con-
glomerates of  lipid and protein molecule-
sol-gel zones. Through the membrane of  
thrombocytes, the substances from throm-
bocyte granules are being released to blood-
stream, but some substances are also ac-
tively carried inside, including serotonin. 
The thrombocyte skeleton is a thick tubu-
lar system consisting of  filaments and mi-
crotubules. It is important for storing and 
regulation of  calcium ion levels and syn-
thesis of  prostaglandins, thromboxane and 
cyclooxygenasis [22]. There is another sys-
tem of  microfilaments which takes part in 
contraction and secretion of  thrombocytes 
and causes the shape change. In the zone 
of  organelles inside the thrombocytes there 
are alpha granules which contain adhesive 
proteins, growth factors and coagulation 
factors and delta granules which, besides 
other active substances and metabolites, 
contain ATP and serotonin. Thrombocyte 
lysosomes contain hydrolytic enzymes and 
peroxisomes with catalase. They have a key 
role in the process of  hemostasis. Qualita-
tive indices of  thrombocytes are: number of  
thrombocytes (Plt), mean volume of  throm-
bocytes (MPV) and thrombocrite (Pct), rou-
tinely available index of  heterogeneity of  
thrombocytes is thewidth of  distribution 
per volume (PDW).
The number of  thrombocytes (Plt) is 
the absolute number of  circulating throm-
bocytes per unit of  blood volume. Physi-
ological values span from 150-400x109/L. 
The mean volume of  thrombocytes - MPV 
(mean platelet volume) is expressed in fem-
toliters (fL) and its clinical significance lies 
in the fact that bigger thrombocytes are 
more reactive and cause creation of  more 
thrombogenic factors [23,24].
The research has been directed towards 
determining the clinical significance of  MPV 
as a potential predictive index of  thrombo-
cyte activation, as a link in the activation of  
atherosclerosis pathogenesis and the devel-
opment of  the acute coronary syndrome. 
Thrombocrite (Pct) represents a volume part 
of  thrombocytes per volume unit of  blood. It 
is calculated as a product of  multiplication of  
MPV and the number of  thrombocytes. The 
reference interval spans from 0.214±0.40% 
[25]. The distribution of  thrombocytes per 
volume – PDW (platelet distribution width) is a 
measure of  heterogeneity of  thrombocytes 
by size. It is used in clinical practice for the 
differential diagnosis of  reactive and primary 
thrombocytosis [26].
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Thrombocyte serotonin and 
thrombocyte characteristics in the 
neurobiology of depression and 
cardiovascular diseases – review of 
the research so far 
The possibilities for exploring the sero-
tonin system in CNS are limited, because of  
the complicated access to samples needed for 
the analysis, which is why the focus of  inves-
tigation has been turned to the investigation 
of  elements of  thrombocyte serotonin sys-
tem. The similarity of  these two serotonin 
system has been discovered at the end of  the 
previous century [27]. The similarity between 
the basic elements has been established: en-
zyme monoaminooxidase, serotonin trans-
porter and 5HT2A receptors. The reason why 
we cannot speak of  being identical, but only 
similar is the fact that serotonin in throm-
bocytes is metabolized by MAO-B, while in 
neurons, it is metabolized by MAO-A. The 
further difference is that a thrombocyte can-
not synthetize serotonin itself, because of  
the lack of  tryptophan hydroxylaze [28,29]. 
Thrombocyte serotonin represents an eas-
ily accessible biological index, and numerous 
studies were designed to investigate its rela-
tions with various forms of  the depressive 
disorder, suicidal behaviour and if  there was 
a connection between it and the response to 
pharmacotherapy [30].  In some of  the stud-
ies made so far, the results have shown that, 
in the patients suffering from  the major de-
pressive disorder, there is a lower level of  
thrombocyte serotonin and that the therapy 
with antidepressants changes some thrombo-
cyte indices. The Takakshi study, from 1976, 
made on 20 patients with unipolar depres-
sion and 19 patients with involutive depres-
sion, 20 of  which had just suffered their first 
depressive episode, compared to 118 healthy 
subjects showed that the concentration of  
thrombocyte serotonin is lower in patients 
with unipolar and involutive depression com-
pared to the healthy volunteers [31]. Samas 
study, from 1987, made on 18 patients suf-
fering from melancholy and compared to 20 
healthy volunteers showed that the concen-
tration of  thrombocyte serotonin is signifi-
cantly lower in patients suffering from mel-
ancholy compared to the healthy volunteers 
[32]. Quintana study, from 1992, done on 
25 untreated depressive patients, compared 
to 25 healthy volunteers showed that the 
concentration of  thrombocyte serotonin is 
lower in depressive patients [33]. The study 
of  Maurej-Spurej et al. from 2004, carried 
out on 27 depressive patients, 13 of  which 
had been untreated and 14 had been tak-
ing SIPPS, showed a lower concentration of  
thrombocyte serotonin in the untreated de-
pressive subjects [34]. In the study present-
ed by Ataoglu and Canan in 2009, they had 
followed 15 patients suffering from the ma-
jor depressive disorder, compared them to 
the group of  healthy volunteers and found 
out that MPV was significantly higher in the 
group of  depressive patients, but no signifi-
cant difference had been found between the 
patients and the control group considering 
the number of  thrombocytes [35]. A signifi-
cant reduction of  MPV, but also a significant 
reduction of  the number of  thrombocytes 
had been found even after an eight-week 
treatment with escitalopram. MPV values had 
stayed higher compared to the control group 
even after eight weeks of  treatment. Patients 
who had suffered a myocardial infarction and 
those with the unstable angina pectoris dis-
play increased values of  MPV compared to 
the patients suffering from the stable angina 
pectoris and compared to the patients with 
chest pain of  non-cardiac origin. An increase 
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of  MPV has been even recognized as an in-
dependent risk factor for the development 
of  myocardial infarction or stroke [36]. In the 
study of  Canan et al. from 2011, the authors 
investigated the relation between MPV, as an 
index of  the activity of  thrombocytes and 
depression in the adult population of  Turkey 
[37]. The study included 2286 subjects and 
revealed significantly higher values of  MPV 
in patients suffering from depression com-
pared to the control group of  healthy volun-
teers. After the exclusion of  other parameters 
that could cause the elevation of  MPV level, 
the value of  MPV in depressive patients was 
still elevated. In the study made by Song et 
al. in 2012, the authors measured the num-
ber of  thrombocytes after the treatment with 
escitalopram, venlafaxine and bupropion 
and found a significantly reduced number of  
thrombocytes after one month of  therapy 
with escitalopram, while there had been no 
significant changes after the treatment with 
other two medications [38].
Selective inhibitors  
of serotonin re-uptake
Antidepressants represent a various group 
of  medications with different mechanisms 
of  action. The tricyclic antidepressants have 
a prominent place among them, because they 
had served as a base for further research. It 
was through them that the importance of  
inhibition of  serotonin and norepinephrine 
reuptake had been determined, as a base for 
the antidepressant action. However, since 
they have a very wide profile of  adverse ef-
fects, they belong among the medicaments 
that are not so well tolerated. Considering the 
antidepressant effect itself, we have not gone 
much further from the tricyclic antidepres-
sants but, on the other hand, the new medi-
cations are better tolerated, which enhances 
the compliance of  patients, thus making the 
course of  therapy easier and more secure in 
given time. The most widely used drugs from 
this group are SIPPS, which are very similar 
to each other and do not differ significant-
ly in their antidepressive affect, but do dif-
fer in the profile of  their adverse effects. The 
mechanism of  action of  SIPPS is blocking 
the serotonin transporter. The process in cen-
tral nervous system occurs in various areas 
of  the brain where the serotoninergic neu-
rons originating from nuclei raphe end. An-
tidepressive effect is achieved when the sero-
tonin transporter is about 80% blocked. As 
a consequence, an increase of  serotonin on 
the synapse occurs, affecting the postsynap-
tic 5HT2A, 5HT2C and 5HT3 receptors, result-
ing in some adverse occurrences in the first 
weeks of  medication. The agonist effect of  
SIPPS on post-synaptic 5HT1A and 5HT4 re-
ceptors leads towards the antidepressive and 
anxiolytic effect. In the beginning of  medica-
tion, SIPPS also cause the stimulation 5HT1A 
pre-synaptic autoreceptors, causing the re-
duction of  serotonin neurons’ activity. Sev-
eral weeks later, the desensitization of  post-
synaptic serotonin receptors occurs, leading 
to the alleviation or the entire regression of  
adverse effects. The beginning of  antidepres-
sive action is connected with returning the 
activity of  serotoninergic neurons back to 
normal and then increased, due to the desen-
sitization of  pre-synaptic 5HT1A receptors. 
However, it is estimated that in 30-50% of  
patients, SIPPS will show no antidepressive 
effect. That is why the medications with dif-
ferent mechanisms of  action are used. The 
following SIPPS drugs are registered in our 
Country and the primary characteristics in 
which they differ are: 1. Fluvoxamine – the 
greatest affinity for sigma receptors, their 
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stimulation leads to an increase of  choliner-
gic and glutaminergic  transmission, which 
has an important influence on cognitive func-
tioning [39]. 2. Fluoxetine – inhibitor of  sero-
tonin 5HT2C receptors, leading to a beneficial 
effect on slow-wave sleep, improvement of  
cognitive functions, antidepressive effect and 
moderate influence on MAO-A and MAO-
B [40]..3. Paroxetine – moderate affinity to 
noradrenergic receptors, anticholinergic ef-
fect, both effects dose-dependent, the most 
potent SIPPS., 4. Sertraline – inhibiting the 
dopamine transporter, increases the level of  
dopamine in nucleus accumbens, affects the 
sigma receptors and the adrenergic alpha 1 
receptors [41]. 5. Citalopram – very strong 
inhibitor of  serotonin reuptake, the stron-
gest affinity for H1 histamine receptors of  all 
SIPPS, with higher doses, one has to consider 
sedation and body weight increase. 6. Escita-
lopram – the most selective inhibitor of  se-
rotonin reuptake, does not affect any other 
receptors, transporters or enzymes, even in 
the highest doses.
The differences between the SIPPS medi-
cations mentioned originate from their phar-
macokinetic characteristics. The elimination 
half-time for citalopram, sertraline, fluvox-
amine and paroxetine equals 24 hours, while 
fluoxetine is an exception and its half-life 
equals 2-4 days for itself  and 7-15 days for its 
metabolite, norfluoxetine. The significant dif-
ferences stem from the ability of  each SIPPS 
to inhibit the enzymes CYP 450, while flu-
voxamine is the least selective and can dras-
tically increase the concentration of  drugs 
which are metabolized through CYP 3A4. 
Paroxetine influences the CYP 2D6 enzyme 
and its inhibition lasts about 3 days [42].
As we already mentioned, in certain num-
ber of  patients with depression, SIPPS will 
not achieve the desired regression of  depres-
sive symptoms and it’s then when we turn to 
the medications with different mechanisms 
of  action. The characteristics of  other groups 
of  antidepressants are 1.dual inhibitors of  se-
rotonin and norepinephrine reuptake: venla-
faxine – in lower doses, affects only the se-
rotonin transporter, while in higher doses 
it affects also the noradrenergic receptor; 
that effect is achieved through blocking the 
MAO-B enzyme; duloxetine – registered also 
for the treatment of  neuropathic pain; that 
effect is achieved through blocking both se-
rotonin and noradrenergic transporter [43]. 
The noradrenergic and the specific sero-
toninergic 5HT2A and 5HT2C blocker (NAS-
SA): mirtazapine - dose-dependent action, 
acts as a histamine receptor blocker (in lower 
doses), serotonin 5HT2A and 5HT2C receptors 
(medium doses), adrenergic alpha 2 receptors 
(higher doses). The modulators of  serotonin 
intake: tianeptine – mechanism of  action is 
insufficiently known, it is believed that it acts 
in such manner as to reduce the quantity of  
available serotonin by means of  increasing 
the serotonin reuptake to neurons. Agonist 
of  melatonin MT1 and MT2 receptors and 
the antagonist of  5HT2C receptors- agomela-
tine – has no effect on other receptors and its 
antidepressive action is the result of  interac-
tion between the receptors mentioned, while 
agomelatin does not affect the level of  sero-
tonin, but changes the level of  increasing the 
dopamine and norepinephrine and affects 
the neuroplasticity [44].
When using the drugs which affect the 
serotonin system, one should be very care-
ful not to cause the development of  toxic 
serotonin syndrome, which occurs because 
of  an increased serotonin activity and hy-
perstimulation of  serotonin receptors, par-
ticularly 5HT1A in spinal cord and brainstem. 
The increase of  norepinephrine, glutamate 
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and dopamine release, as a consequence of  
an increased serotonin activity, also produces 
symptoms in the frame of  a toxic serotonin 
syndrome [45].
Discussion and conclusions
Considering the fact that the course of  
recovery from many diseases can be compli-
cated by the occurrence of  depression, which 
is particularly accentuated in cardiovascular 
diseases, timely recognition and successful 
treatment of  depression directly influences 
the course of  recovery and finally, the mor-
tality, because the depression is related to the 
increased mortality in those patients. Besides 
the fact that the depressive behaviour dis-
turbs the recovery of  patients, it also reduces 
the personal engagement in recovery, com-
pliance and motivation of  patients, which is 
a very important role, but an important role 
belongs also to the thrombocyte serotonin 
in pathogenesis of  cardiovascular diseases, 
especially the coronary heart disease and its 
complications. The thrombocyte serotonin 
is one of  the factors in coagulation process, 
which is, on the other hand, one of  the most 
important mechanism that connect depres-
sion with the coronary heart disease. The 
prevalence of  depression in patients with 
coronary heart disease spans from 16-23%. 
Numerous studies have shown that besides 
hyperlipidemia, hypertension, obesity, diabe-
tes and smoking, depression also represents 
an independent risk factor for the develop-
ment of  coronary heart disease [46]. The 
presence of  depression is a bad prognostic 
sign for patients who had already suffered a 
heart attack. The depressive patients have 3-4 
times greater risk of  developing the cardio-
vascular complications compared to the non-
depressive patients [47]. Thrombocytes play 
the central role in the development of  ath-
erosclerosis, thrombosis and the acute coro-
nary syndromes. It is considered that one of  
the reasons for the previously mentioned in-
creased risk is a dysfunction, i.e. increased ac-
tivity of  thrombocytes in depressive patients 
[48]. Serotonin secreted by alpha granules is 
a very potent vasoconstrictor, which increas-
es the cardiovascular risk and the probabil-
ity of  thrombi formation. Some changes of  
physiological characteristics of  thrombocytes 
present in depressive patients, such as mobi-
lization of  calcium inside the thrombocytes, 
up-regulation of  serotonin receptors and al-
pha 2 adrenoreceptors, down-regulation of  
serotonin transporters, changing the signal 
of  the second messenger, i.e. changes of  
levels of  monoamines and cateholamines in 
thrombocytes can have a negative effect on 
thrombocyte function, namely strengthen 
the processes of  coagulation and throm-
bogenesis [49]. Thus, we can conclude that 
serotonin plays important roles both in the 
neurobiology of  depression and in throm-
bogenesis [50]. There have been studies that 
tried to explain the connection between the 
level of  thrombocyte serotonin in the acute 
coronary syndrome in patients with and 
without the symptoms of  depression and 
determine if  there was a linear correlation 
between them. In the study made by Sanner 
et al. in 2013, the authors could not find a 
linear correlation. The study concludes that 
the correlation between the thrombocyte se-
rotonin, depressive symptoms and the acute 
coronary syndrome is not yet fully explained, 
but there is a number of  clues that suggest 
such correlation [51]. The SIPPS act in such 
manner that their action reduces the level 
of  the available serotonin, which is reflect-
ed in lower levels of  serotonin in thrombo-
cytes. The data for individual SIPPS suggest 
that, for example, sertraline in vitro causes 
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the inhibition of  thrombocyte aggregation, 
depending on its dose [52]. After six weeks 
of  therapy with paroxetine, a normalization 
of  thrombocyte activity can be observed in 
depressive patients, both in those with and 
those without the coronary heart disease [53]. 
Similarly. The study made by Glassman et al 
in 2002 showed that the depressive patients 
who had suffered a heart attack and had been 
treated with sertraline during the period of  
24 weeks had a smaller number of  the acute 
coronary incidents compared to patients who 
had been treated with placebo [54]. However, 
the difference was not statistically significant, 
but considering the high incidence of  cardio-
vascular diseases (especially ischemic heart 
disease) in population, even such difference 
should not be neglected. 
A positive index of  thrombocyte activ-
ity is MPV [55]. In the study by Ataoglu and 
Canan from 2009, the results have shown a 
decrease of  MPV values after an eight-week 
treatment with escitalopram. The increased 
values of  MPV have been detected in pa-
tients with unstable angina pectoris and pa-
tients who had suffered a heart attack. That 
is why an increase of  MPV has been recog-
nized as an independent risk factor for the 
development of  both stroke and a heart at-
tack [56]. It has been proved that the size of  
thrombocytes, measured as a mean value of  
thrombocytes’ volume (MPV) is correlated 
with their reactivity [57].
In concordance with the facts listed above, 
we are at liberty to conclude that the timely 
detection of  depression in patients with car-
diovascular diseases is, particularly after the 
coronary incidents, of  the utmost impor-
tance. The treatment of  depression direct-
ly influences the recovery of  those patients 
and reduces the incidence of  complications. 
The antidepressants from SIPPS group has 
a special role in the treatment of  depression. 
These medications display a positive effect 
on the recovery through the improvement 
of  mental status and there is also clear evi-
dence that they reduce the concentration of  
thrombocyte serotonin and the mean volume 
of  thrombocytes, which both have an impor-
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Uloga trombocitnog serotoninskog sustava i nekih karakteristika trombocita u 
liječenju depresivnih pacijenata s kardiovaskularnim bolestima.
Sažetak – U razvoju depresivnog poremećaja serotonin ima vrlo važnu ulogu. S obzirom da su direktna 
istraživanja u području centralnog živčanog sustava čovjeka dobrim dijelom nedostupna istraživačima zbog 
nedostupnosti uzimanja uzoraka, sve veća važnost se pridaje perifernim sustavima koji nam mogu pomoći u 
dijagnozi, detekciji promjena u samoj bolesti, ali i u praćenju liječenja i oporavka. Trombocit je krvno tjelešce 
koje u svojim delta granulama sadrži serotonin. Trombocitni serotoninski sustav je sličan, ne i istovjetan sero-
toninskom sustavu u centralnom živčanom sustavu. Najbitnija je razlika što u trombocitu serotonin razgrađuje 
enzim monoaminooksidaza B (MAO-B), a u neuronu monoaminooksidaza A (MAO-A), te što trombocit ne 
može sam sintetizirati serotonin jer mu nedostaje triptofan hidroksilaza. U liječenju depresivnog poremećaja 
danas se najviše koriste selektivni inhibitori ponovne pohrane serotonina (SIPPS). Istraživanja su dokazala da 
terapija navedenim lijekovima mijenja koncentraciju serotonina u trombocitima, te mijenja vrijednosti nekih 
trombocitnih pokazatelja. Trombocitni serotonin je snažan vazokonstriktor, povećava kardiovaskularni rizik i 
vjerojatnost formiranja tromba. Srednji volumen trombocita (MPV) je pozitivan pokazatelj trombocitne ak-
tivnosti, te je povišeni MPV nezavisni faktor rizika od kardiovaskularnih incidenata. Od izuzetno velike važnosti 
je prepoznavanje depresije kod pacijenata koji boluju od kardiovaskularnih bolesti. Depresija narušava opora-
vak tih bolesnika jer reducira osobni angažman u oporavku, suradljivost i motivaciju za liječenje. Osim što 
liječenje SIPPS-ima dovodi do oporavka simptoma depresije, ono mijenja koncentraciju trombocitnog sero-
tonina i srednji volumen trombocita u smjeru vrijednosti koje smanjuju njihove uloge u patogenezi kardio-
vaskularnih bolesti čime se smanjuje rizik ponavljanja kardiovaskularnih incidenata i poboljšava se oporavak 
bolesnika.
Ključne riječi: serotonin, trombociti, SIPPS depresija, kardiovaskularne bolest
